



Event Page & Program Book

### The Alzheimer's Disease Patient Journey: Pathways to Early-Stage Screening and Detection

Kaiser Permanente Center for Total Health Washington DC May 23, 2024 | 1:00 – 5:00 PM ET





Network for Excellence in Health Innovation

# About NEHI

- NEHI is a national non-profit, non-partisan organization composed of stakeholders from across key sectors of health and health care
- Through interdisciplinary collaboration and with our members' guidance, we research and examine complex and timely health care innovation issues from multiple, often divergent, perspectives.
- We then address policy and adoption challenges to promote the value of innovative products and processes.

# 'Thank You' to Our Project Sponsors!



Event Page & Program Book





### NEHI's previous work on dementia & Alzheimer's



Diagnosing Hope: The New Era of Alzheimer's Disease Treatment Hinges on Innovations in Diagnostics

A NEHI Report

October 2023

### **Key Findings**

- A new era in Alzheimer's disease care has begun
- The health care system will now face the challenge of gaining capability for accurate and cost-effective testing for Alzheimer's disease – at greater scale
- The first step includes overcoming barriers to uptake of cerebrospinal fluid (CSF) analysis and PET imaging and fostering adoption of blood-based and other fluid biomarker testing
- Expanding the toolbox for screening and assessment of Mild Cognitive Impairment, dementia, Alzheimer's, and other neurodegenerative conditions will be essential
- The ideal goal is "right test, right time, right patient" a paradigm shift in dementia screening and care



# Ability to Detect vs. Capability to Adopt



#### The Economist

Science & technology

Nov 13th 2021 edition

Subscribe

#### Knowing the worst

It is becoming easier, cheaper and quicker to diagnose dementia

### A New Alzheimer's Drug is Finally Here – Our Healthcare System is Far from Ready

The new year always brings hope, but this January that hope was palpable for the  $\left[ \ldots \right]$ 

By DR. ALVARO PASCUAL-LEONE

Post a comment / Apr 13, 2023 at 10:26 AM

EDITORIAL

Evidence Still Lacking for Recommendation of Screening for Cognitive Impairment in Older Adults Carol Brayne, MD

Carol Brayne MD, JAMA Internal Medicine, April 2020

## Mild Cognitive Impairment (MCI) & Dementia



etwork for Excellence

#### Prevalence

- Manly et al 2022: 10% prevalence of dementia and 22% prevalence of MCI identified in random sample of subjects 65 years+ enrolled in the national Health and Retirement Study (HRS). (N=3496)
- MCI and dementia risk seen to increase with age and decrease with each additional year of education
- Dementia more prevalent among non-Hispanic Black Americans, MCI more prevalent among Hispanic individuals compared to non-Hispanic Whites.

### Screening

- Jacobson et al 2020: *Approximately 30% of Medicaid beneficiaries receive a cognitive assessment at any physician visit*
  - Assessment rates higher among Medicare Advantage subscribers
  - Cognitive assessment rates lower in Medicare Annual Wellness Visits than in visits overall

#### Detection

- Liu et al 2023: Detection rate of MCI in Medicare beneficiaries among PCPs and PCP practices (2017-2019) = 8 percent
  - (N=226,756 PCPs, 54,507 PCP practices, detection rate= Observed rate/Predicted rate)

## **Barriers to Increased Screening**



letwork for Excellence

#### NAVIGATING AGING

#### Stalked By The Fear That Dementia Is Stalking You

By Judith Graham • FEBRUARY 21, 2020



#### Barriers cited in a systematic review of the literature\*

Clinicians' hesitancy to discuss brain health and cognitive concerns

Patients' hesitancy to raise cognitive concerns

Evidence to guide clinicians on treatment of cognitive decline often poorly communicated

Social and cultural context influence perceptions of brain health and cognition, thus affecting clinical engagement

\*Borson et al., 2023

# Typical Care and Referral to Specialists



Network for Excellence







## **Innovations Enable Early Detection**











Implications for Diagnosis of Alzheimer's Disease: Alzheimer's Association Workgroup "Revised Criteria for Diagnosis and Staging of Alzheimer's Disease"

Stage 0: Asymptomatic, biomarkers in normal range Stage 1: Asymptomatic, biomarker evidence only

**Stage 2:** Transitional decline: Mild detectable change, but minimal impact on daily function

Stage 3: Cognitive impairment with early functional impact

**Stage 4:** Dementia with mild functional impairment

Stage 5: Dementia with moderate functional impairment

Stage 6: Dementia with severe functional impairment

### Oncoming Innovations for Screening and Assessment of Mild Cognitive Impairment and Dementia



in Health Innovation



Joshua Soldo Chief Scientific Officer & Co-Founder, Veravas, Inc.

Deborah E. Barnes, PhD, MPH Professor, Departments of **Psychiatry and Behavioral** Sciences and Epidemiology & **Biostatistics**, UCSF Weill Institute for Neurosciences and **Osher Center for Integrative** Health, UCSF



**David Bates, PhD** CEO & Co-Founder, Linus Health

James Hendrix, PhD **Executive Director for U.S. Medical Affairs** Eli Lilly & Company

> Todd Levine, MD Chief Medical Officer & Co-Founder; Clinical Neurologist **CND** Life Sciences



Up Next: Implications for Clinical Practice and Healthcare Policy of Oncoming Innovations in MCI and Dementia Screening and Assessment









Angela Hsu, MD Physician Director of Memory Care Services, *Mid-Atlantic* Permanente Medical Group





Scott Sarran, MD, MBA Chief Medical Officer, Harmonic Health





Julie K. Wood, MD, MPH, FAAFP Senior Vice President of Science and Clinical Strategy, American Academy of Family Physicians; Family Physician



## Thank You!

NEHI will share the recording and materials from today's event via email next week.

### Contacts:

Tom Hubbard (<u>thubbard@nehi-us.org</u>) Lauren Bedel (<u>lbedel@nehi-us.org</u>) Maya Valadez (<u>intern2@nehi-us.org</u>)